HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial

TigerDec 9, 2025 1:37 AM

View all comments（0）



Ascletis Pharma surged 23.3% in Hong Kong.

Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Tesla Stock Price Forecast: Morgan Stanley Sees Semi Truck Generating $17 Billion in Software Revenue, Can the Stock Continue Its Recovery?

On September 11, Tesla (TSLA) officially unveiled the European-spec version of the Semi and confirmed that customer deliveries will begin in 2027. Tesla is expected to showcase the physical vehicle and release further market rollout details at the IAA Transportation commercial vehicle show in Hanover (September 15–20). Meanwhile, Morgan Stanley noted in its latest research report that Tesla is becoming a "credible emerging competitor" in the autonomous trucking sector, significantly raising its bull-case valuation for the company's autonomous truck business.

Anthropic Targets $2 Trillion Valuation as 2026 US IPO Proceeds Hit Record, Yet New Stocks Lag Market

TradingKey - US IPO proceeds in 2026 have reached a record high, but post-IPO stock performance has not strengthened in tandem. As companies like Oura and Anthropic move forward with their listings, September and October will further test investor appetite for high-valuation new stocks.

SpaceX Stock Price Forecast: As Stock Lockups Intensify, Can SPCX Peak at $225 by 2027?

SpaceX employs a phased, rolling share unlock mechanism. Although frequent share releases create potential selling pressure, strong earnings results and buying interest have successfully absorbed the market supply. As the lockup expirations conclude by mid-2027, this selling overhang will dissipate, giving SpaceX the potential to reclaim its $225 high. However, sustained momentum will still require fundamental catalysts such as Starlink profitability and the commercialization of Starship.

Qualcomm Stock Holds Rising Trendline as Amazon AI Deal Puts $182.70 Breakout in Focus

TradingKey - Qualcomm stock forecast, QCOM technical analysis, Qualcomm Amazon AI deal, Dragonfly data center, Qualcomm automotive growth

Copper Surges to Record High: Which Copper Stocks Are Worth Watching?

Copper prices recently reached an all-time high of $14,533, registering a cumulative gain of 17% over the past year. Underpinning this record rally is a long-standing narrative championed by copper bulls for years: aging major global mines struggle to keep pace with demand growth driven by AI data centers, renewable energy, and power grid construction. The gains over the past year have been supported precisely by this long-term supply-demand mismatch.

Featured Tools